Tech Company Financing Transactions
Elixir Pharmaceuticals Funding Round
Elixir Pharmaceuticals closed a $40.5 million Series B financing round on 10/13/2003. Investors included Arch Venture Partners, MPM Capital and Oxford Bioscience Partners.
Transaction Overview
Company Name
Announced On
10/13/2003
Transaction Type
Venture Equity
Amount
$40,500,000
Round
Series B
Proceeds Purpose
These funds will be put to good use in developing our lead compounds for a number of these disease indications. technology and markets we serve.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
300 Putnam Avenue
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Elixir Pharmaceuticals is a genomics-based drug discovery company developing a new category of pharmaceuticals that treat and/or prevent the broad spectrum of diseases that accompany aging.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Paul Martha
Chief Scientific Officer
Peter DiStefano
VP - Finance
Karen Roberts
Browse more venture capital transactions:
Prev: 10/8/2003: Critical Technologies venture capital transaction
Next: 10/13/2003: OpVista venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs